Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis

Company Overview

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

Key Stats

• Today's Range: $0.41 to $0.43
• 50-Day Range: $0.32 to $0.49
• 52-Week Range: $0.12 to $0.75
• Volume: 477,291 shs
• Average Volume: 934,715 shs
• Market Capitalization: $446.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Elite Pharmaceuticals Stock Analysis - MarketRank™

Elite Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Elite Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Elite Pharmaceuticals is -20.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Elite Pharmaceuticals is -20.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Elite Pharmaceuticals has a P/B Ratio of 13.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.22% of the float of Elite Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently increased by 1.02%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Elite Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Elite Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.22% of the float of Elite Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Elite Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Elite Pharmaceuticals has recently increased by 1.02%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Elite Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Elite Pharmaceuticals this week, compared to 0 articles on an average week.

Search Interest

Only 1 people have searched for ELTP on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.01% of the stock of Elite Pharmaceuticals is held by institutions.

ELTP Stock Analysis - Frequently Asked Questions

How have ELTP shares performed this year?

Elite Pharmaceuticals' stock was trading at $0.5411 at the beginning of 2025. Since then, ELTP stock has decreased by 22.7% and is now trading at $0.4181.
View the best growth stocks for 2025 here.

How were Elite Pharmaceuticals' earnings last quarter?

Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP) released its earnings results on Thursday, February, 13th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter. Elite Pharmaceuticals had a negative net margin of 25.70% and a negative trailing twelve-month return on equity of 6.92%.
Read the conference call transcript.

How do I buy shares of Elite Pharmaceuticals?

Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elite Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO).

Company Calendar

• Last Earnings: 2/13/2025
• Today: 5/06/2025
• Next Earnings (Estimated): 6/30/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ELTP
• CIK: 1053369
• Web: www.elitepharma.com
• Phone: (201) 750-2646
• Fax: 201-750-2755
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $20.11 million
• Net Margins: -25.70%
• Pretax Margin: -24.76%
• Return on Equity: -6.92%
• Return on Assets: -3.94%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.27
• Quick Ratio: 1.90

Sales & Book Value

• Annual Sales: $56.62 million
• Price / Sales: 7.89
• Cash Flow: $0.02 per share
• Price / Cash Flow: 16.94
• Book Value: $0.03 per share
• Price / Book: 13.94

Miscellaneous

• Outstanding Shares: 1,068,363,000
• Free Float: 914,305,000
• Market Cap: $446.68 million
• Optionable: Not Optionable
• Beta: 0.04